Free Trial

Cytokinetics (CYTK) 10K Form and Latest SEC Filings 2026

Cytokinetics logo
$74.29 -0.55 (-0.73%)
Closing price 04:00 PM Eastern
Extended Trading
$73.97 -0.32 (-0.42%)
As of 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Cytokinetics SEC Filings & Recent Activity

Cytokinetics (NASDAQ:CYTK) has submitted 839+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Cytokinetics's financial statements. The most recent filing was a Form 424B5 submitted on May 7, 2026.

Form 4
CYTOKINETICS INC Reports Ownership Change on May. 5, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Cytokinetics Files Current Report on May. 5, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Cytokinetics Files Quarterly Report on May. 5, 2026

The 10-Q contains Cytokinetics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Cytokinetics SEC Filing History

Browse Cytokinetics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/07/2026 4:19 PM
Cytokinetics (1061983) Filer
Form 424B5
05/06/2026 10:13 AM
Cytokinetics (1061983) Subject
FMR LLC (315066) Filed by
Form SCHEDULE 13G/A
05/05/2026 4:35 PM
Cytokinetics (1061983) Issuer
Malik Fady Ibraham (1551778) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 3:45 PM
Cytokinetics (1061983) Filer
Form 424B5
05/05/2026 3:31 PM
Cytokinetics (1061983) Subject
Lee Sung (1793200) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/05/2026 3:31 PM
Cytokinetics (1061983) Subject
HENDERSON JOHN T (1226488) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/05/2026 3:33 PM
Cytokinetics (1061983) Subject
WIERENGA WENDELL (1239956) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/05/2026 3:18 PM
Cytokinetics (1061983) Issuer
Lee Sung (1793200) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 3:20 PM
Cytokinetics (1061983) Issuer
WIERENGA WENDELL (1239956) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 3:05 PM
Cytokinetics (1061983) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/05/2026 3:06 PM
Cytokinetics (1061983) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/29/2026 5:08 PM
Cytokinetics (1061983) Subject
VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by
Form SCHEDULE 13G
04/21/2026 3:22 PM
Cytokinetics (1061983) Issuer
Malik Fady Ibraham (1551778) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/17/2026 3:05 PM
Cytokinetics (1061983) Filer
Form DEF 14A
04/17/2026 3:06 PM
Cytokinetics (1061983) Filer
Form ARS
04/15/2026 5:37 PM
Cytokinetics (1061983) Issuer
Wysenski Nancy (1294596) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 5:32 PM
Cytokinetics (1061983) Issuer
Daly James M (1560782) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 5:33 PM
Cytokinetics (1061983) Issuer
Harrington Robert Arthur (1923988) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 5:34 PM
Cytokinetics (1061983) Issuer
HENDERSON JOHN T (1226488) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 5:35 PM
Cytokinetics (1061983) Issuer
Kaye Edward M. MD (1522780) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 5:36 PM
Cytokinetics (1061983) Issuer
WIERENGA WENDELL (1239956) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 4:27 PM
Blum Robert I (1288859) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 4:29 PM
Callos Andrew (1852129) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 3:55 PM
Callos Andrew (1852129) Reporting
Cytokinetics (1061983) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/08/2026 3:18 PM
Cytokinetics (1061983) Issuer
Malik Fady Ibraham (1551778) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/07/2026 3:26 PM
Cytokinetics (1061983) Subject
Malik Fady Ibraham (1551778) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/01/2026 3:47 PM
Blum Robert I (1288859) Reporting
Cytokinetics (1061983) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/01/2026 3:34 PM
Blum Robert I (1288859) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/31/2026 3:21 PM
Callos Andrew (1852129) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/26/2026 4:41 PM
Cytokinetics (1061983) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/18/2026 4:37 PM
Blum Robert I (1288859) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2026 4:40 PM
Cytokinetics (1061983) Issuer
Malik Fady Ibraham (1551778) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2026 4:43 PM
Callos Andrew (1852129) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2026 4:46 PM
Cytokinetics (1061983) Issuer
Lee Sung (1793200) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2026 3:55 PM
Callos Andrew (1852129) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/16/2026 4:14 PM
Callos Andrew (1852129) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/16/2026 3:39 PM
Callos Andrew (1852129) Reporting
Cytokinetics (1061983) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/10/2026 5:00 PM
Blum Robert I (1288859) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2026 5:03 PM
Cytokinetics (1061983) Issuer
Malik Fady Ibraham (1551778) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2026 5:05 PM
Callos Andrew (1852129) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 3:27 PM
Callos Andrew (1852129) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2026 4:35 PM
Cytokinetics (1061983) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/26/2026 3:01 PM
Cytokinetics (1061983) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/17/2026 9:28 AM
Cytokinetics (1061983) Subject
T. Rowe Price Investment Management, Inc. (1897612) Filed by
Form SCHEDULE 13G/A
02/17/2026 6:30 AM
Cytokinetics (1061983) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/05/2026 7:17 PM
Callos Andrew (1852129) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/02/2026 3:40 PM
Callos Andrew (1852129) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/16/2026 3:18 PM
Cytokinetics (1061983) Issuer
Kaye Edward M. MD (1522780) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/16/2026 3:20 PM
Cytokinetics (1061983) Issuer
WIERENGA WENDELL (1239956) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/16/2026 3:22 PM
Cytokinetics (1061983) Issuer
Wysenski Nancy (1294596) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/16/2026 3:15 PM
Cytokinetics (1061983) Issuer
Harrington Robert Arthur (1923988) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/16/2026 3:17 PM
Cytokinetics (1061983) Issuer
HENDERSON JOHN T (1226488) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/02/2026 5:01 PM
Callos Andrew (1852129) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/02/2026 3:34 PM
Callos Andrew (1852129) Reporting
Cytokinetics (1061983) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/30/2025 3:34 PM
Callos Andrew (1852129) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2025 3:27 PM
Callos Andrew (1852129) Reporting
Cytokinetics (1061983) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/29/2025 3:09 PM
Blum Robert I (1288859) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 3:26 PM
Blum Robert I (1288859) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 3:13 PM
Cytokinetics (1061983) Issuer
WIERENGA WENDELL (1239956) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/22/2025 3:26 PM
Cytokinetics (1061983) Subject
WIERENGA WENDELL (1239956) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/19/2025 3:01 PM
Cytokinetics (1061983) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/16/2025 3:29 PM
Cytokinetics (1061983) Issuer
Malik Fady Ibraham (1551778) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2025 7:54 AM
Cytokinetics (1061983) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/08/2025 4:28 PM
Callos Andrew (1852129) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/05/2025 4:35 PM
Callos Andrew (1852129) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/05/2025 3:25 PM
Cytokinetics (1061983) Issuer
Lee Sung (1793200) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/05/2025 3:26 PM
Callos Andrew (1852129) Reporting
Cytokinetics (1061983) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/02/2025 4:10 PM
Cytokinetics (1061983) Issuer
Malik Fady Ibraham (1551778) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/02/2025 4:14 PM
Cytokinetics (1061983) Issuer
HENDERSON JOHN T (1226488) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/02/2025 3:25 PM
Cytokinetics (1061983) Subject
HENDERSON JOHN T (1226488) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/02/2025 8:18 AM
Cytokinetics (1061983) Issuer
Kaye Edward M. MD (1522780) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/02/2025 8:13 AM
Cytokinetics (1061983) Issuer
Harrington Robert Arthur (1923988) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 3:21 PM
Cytokinetics (1061983) Subject
Kaye Edward M. MD (1522780) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/19/2025 5:57 PM
Cytokinetics (1061983) Issuer
PARSHALL B LYNNE (1073385) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 3:20 PM
Cytokinetics (1061983) Subject
PARSHALL B LYNNE (1073385) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/17/2025 3:02 PM
Cytokinetics (1061983) Issuer
Hessekiel Jeffrey (1599803) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2025 8:56 PM
Cytokinetics (1061983) Issuer
Hessekiel Jeffrey (1599803) Reporting
Form 3
Initial statement of beneficial ownership of securities  
11/14/2025 3:05 PM
Cytokinetics (1061983) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2025 11:18 AM
Cytokinetics (1061983) Subject
T. Rowe Price Investment Management, Inc. (1897612) Filed by
Form SCHEDULE 13G/A
11/12/2025 5:50 PM
Cytokinetics (1061983) Issuer
Kaye Edward M. MD (1522780) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/12/2025 6:04 AM
Cytokinetics (1061983) Subject
Kaye Edward M. MD (1522780) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/10/2025 7:27 AM
Cytokinetics (1061983) Subject
STATE STREET CORP (93751) Filed by
STATE STREET CORP (93751) Filed by
Form SCHEDULE 13G
11/05/2025 3:31 PM
Cytokinetics (1061983) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/05/2025 3:22 PM
Blum Robert I (1288859) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/04/2025 6:23 PM
Cytokinetics (1061983) Issuer
Malik Fady Ibraham (1551778) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/27/2025 4:59 PM
Cytokinetics (1061983) Issuer
WIERENGA WENDELL (1239956) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/27/2025 3:27 PM
Cytokinetics (1061983) Subject
WIERENGA WENDELL (1239956) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/21/2025 5:18 PM
Cytokinetics (1061983) Issuer
Malik Fady Ibraham (1551778) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/21/2025 3:20 PM
Cytokinetics (1061983) Subject
Malik Fady Ibraham (1551778) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/21/2025 11:22 AM
Cytokinetics (1061983) Issuer
WIERENGA WENDELL (1239956) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2025 4:05 PM
Blum Robert I (1288859) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2025 3:37 PM
Cytokinetics (1061983) Issuer
Harrington Robert Arthur (1923988) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2025 3:32 PM
Cytokinetics (1061983) Issuer
Wysenski Nancy (1294596) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2025 3:34 PM
Cytokinetics (1061983) Issuer
Kaye Edward M. MD (1522780) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2025 3:36 PM
Cytokinetics (1061983) Issuer
HENDERSON JOHN T (1226488) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/07/2025 4:08 PM
Cytokinetics (1061983) Issuer
Malik Fady Ibraham (1551778) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/06/2025 3:22 PM
Cytokinetics (1061983) Subject
Kaye Edward M. MD (1522780) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/06/2025 3:27 PM
Cytokinetics (1061983) Issuer
Kaye Edward M. MD (1522780) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/01/2025 3:34 PM
Blum Robert I (1288859) Reporting
Cytokinetics (1061983) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/01/2025 3:26 PM
Blum Robert I (1288859) Reporting
Cytokinetics (1061983) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)

Cytokinetics SEC Filings - Frequently Asked Questions

Cytokinetics (CYTK) has submitted 839+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Cytokinetics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Cytokinetics's financial statements page.

The most recent filing was a Form 424B5 submitted on May 7, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:CYTK) was last updated on 5/7/2026 by MarketBeat.com Staff.
From Our Partners